These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11740818)

  • 1. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
    Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
    Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
    Gupta D; Treon SP; Shima Y; Hideshima T; Podar K; Tai YT; Lin B; Lentzsch S; Davies FE; Chauhan D; Schlossman RL; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling DI; Anderson KC
    Leukemia; 2001 Dec; 15(12):1950-61. PubMed ID: 11753617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving disease biology from the lab to the clinic.
    Anderson KC
    Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential new therapeutics for Waldenstrom's macroglobulinemia.
    Zeldis JB; Schafer PH; Bennett BL; Mercurio F; Stirling DI
    Semin Oncol; 2003 Apr; 30(2):275-81. PubMed ID: 12720152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
    Hideshima T; Akiyama M; Hayashi T; Richardson P; Schlossman R; Chauhan D; Anderson KC
    Blood; 2003 Jan; 101(2):703-5. PubMed ID: 12393542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
    Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
    Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Akiyama M; Richardson P; Schlossman RL; Chauhan D; Munshi NC; Waxman S; Anderson KC
    Mol Cancer Ther; 2002 Aug; 1(10):851-60. PubMed ID: 12492118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
    Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC
    Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
    Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.